🟢 Compass Pathways is trading 6.3% up today after Q2 results and reaffirmed COMP360 launch timeline

Compass Pathways is trading at $12.54 (up 6.3%) after reporting Q2 2026 results that confirmed a strong cash position and reaffirmed the regulatory timeline for its COMP360 program.

• The company reported a $433.3 million cash position and confirmed its rolling NDA submission for COMP360 remains on track for completion in Q4 2026.
• Management guided toward a potential commercial launch in the first half of 2027, offsetting a wider net loss caused by a non-cash warrant liability adjustment.
• Sentiment is further bolstered by a broader rally in the biotech sector, which is trading approximately 2% higher today.